机构:[a]Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China[b]Department of Orthopedic Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China外科系统骨科浙江大学医学院附属第一医院[c]Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China[d]Department of Cardiology, Beijing Anzhen Hospital of Capital Medical University, Beijing, China临床科室心脏内科中心首都医科大学附属安贞医院[e]Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Cardiac stromal cells (CSCs) can be derived from explant cultures, and a subgroup of these cells is viewed as cardiac mesenchymal stem cells due to their expression of CD90. Here, we sought to determine the therapeutic potential of CD90-positive and CD90-negative CSCs in a rat model of chronic myocardial infarction. We obtain CD90-positive and CD90-negative fractions of CSCs from rat myocardial tissue explant cultures by magnetically activated cell sorting. In vitro, CD90-negative CSCs outperform CD90-positive CSCs in tube formation and cardiomyocyte functional assays. In rats with a 30-day infarct, injection of CD90-negative CSCs augments cardiac function in the infarct in a way superior to that from CD90-positive CSCs and unsorted CSCs. Histological analysis revealed that CD90-negative CSCs increase vascularization in the infarct. Our results suggest that CD90-negative CSCs could be a development candidate as a new cell therapy product for chronic myocardial infarction.
基金:
National Natural Science Foundation of China-Henan Talent Training Fund [U1404802]; Key Project for Science and Technology Research of Henan Department of Education [13A320623]; UNC General Assembly ROI award
第一作者机构:[a]Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
共同第一作者:
通讯作者:
通讯机构:[a]Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China[e]Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
推荐引用方式(GB/T 7714):
Deliang Shen,Miaoda Shen,Hongxia Liang,et al.Therapeutic benefits of CD90-negative cardiac stromal cells in rats with a 30-day chronic infarct[J].JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2018,22(3):1984-1991.doi:10.1111/jcmm.13517.
APA:
Deliang Shen,Miaoda Shen,Hongxia Liang,Junnan Tang,Bo Wang...&Thomas G. Caranasos.(2018).Therapeutic benefits of CD90-negative cardiac stromal cells in rats with a 30-day chronic infarct.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,22,(3)
MLA:
Deliang Shen,et al."Therapeutic benefits of CD90-negative cardiac stromal cells in rats with a 30-day chronic infarct".JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 22..3(2018):1984-1991